CYP17A and 5-α-reductase Inhibitor Combination for CRPC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Castration-resistant prostate cancer (CRPC) develops resistance to current therapies by converting precursor steroids to testosterone and dihydrotestosterone, and existing treatments like abiraterone have limitations due to metabolism issues, leading to stimulation of the androgen receptor and tumor growth.
Innovation Solution
Administering a combination of a CYP17A inhibitor, such as abiraterone, and a 5-α-reductase inhibitor to block the conversion of D4A to 5α-abiraterone, which stimulates the androgen receptor, thereby inhibiting multiple steps in the androgen pathway and preventing tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If abiraterone is administered to block androgen synthesis, then androgen production is inhibited, but the metabolite 5α-abiraterone is formed which stimulates the androgen receptor and promotes tumor growth
Solution Approach 1:
The patent converts the harmful metabolite 5α-abiraterone (which stimulates androgen receptors) into a beneficial component by co-administering it with the parent compound abiraterone. The combination allows the harmful metabolite to be present without causing net harm, as the parent compound's inhibition of androgen synthesis outweighs the metabolite's stimulatory effect, while the metabolite may provide additional therapeutic benefits through androgen receptor modulation.
Solution Approach 2:
The patent uses the metabolic relationship between abiraterone and 5α-abiraterone as an intermediary mechanism. By understanding and leveraging the metabolic conversion pathway, the invention transforms an unintended harmful byproduct into a controlled therapeutic element, where the metabolite serves as a mediator that can be managed through combination therapy rather than eliminated.
2Reliability
If abiraterone is used to treat prostate cancer, then initial response is achieved, but resistance develops as tumors convert precursor steroids to active androgens
Solution Approach 1:
The patent segments the androgen synthesis pathway into multiple targets by combining abiraterone (which inhibits CYP17A1 and blocks androgen synthesis at an early step) with 5α-reductase inhibitors (which block conversion of testosterone to dihydrotestosterone at a later step). This multi-point intervention prevents tumors from bypassing one block by activating alternative pathways, thereby extending treatment duration and overcoming resistance.
Solution Approach 2:
The patent changes the therapeutic parameters from single-agent inhibition of androgen synthesis to dual-agent inhibition of both androgen synthesis and activation. This parameter change from monotherapy to combination therapy with different mechanisms of action addresses the resistance issue by simultaneously blocking multiple enzymatic steps in the androgen pathway, preventing compensatory metabolic adaptations.
3Power
If D4A is produced as a metabolite of abiraterone, then potent antitumor activity is achieved, but D4A is further metabolized to 5α-abiraterone which counteracts the therapeutic effect
Solution Approach 1:
The patent applies preliminary action by co-administering 5α-reductase inhibitors with abiraterone before the harmful metabolism of D4A to 5α-abiraterone can occur. This preemptive blockade of the 5α-reductase enzyme prevents the conversion of the potent antitumor metabolite D4A into the less active 5α-abiraterone, thereby preserving the therapeutic potency throughout the treatment duration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination effectively blocks androgen synthesis and receptor stimulation, leading to more potent antitumor activity than abiraterone alone, delaying tumor progression and improving treatment outcomes for CRPC.
Implementation Method 1
Abiraterone, a steroidal CYP17A inhibitor, blocks this process predominantly by inhibiting the enzyme CYP17A, which is required for androgen synthesis
Implementation Method 2
conversion of D4A to 5α-abiraterone can be pharmacologically blocked by 5-α-reductase inhibitors
Implementation Method 3
D4A can be metabolized further in patients and is converted by steroid 5-α-reductase to 5α-abiraterone
Data Source
AI summary
A method of treating steroid-dependent disease such as prostate cancer in a subject is described that includes administering a therapeutically effective amount a CYP17A inhibitor and an effective amount of a 5-α-reductase inhibitor to the subject.